Post date
09/09/2021
Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the
Post date
01/09/2021
European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.
Excellent news for people at risk of
Post date
30/06/2021
This new fundraising secures the financing of its Phase IIB study for HepaStem® in its flagship indication, Acute on Chronic Liver Failure (ACLF), a severe liver disease affecting more than 50000
Post date
29/06/2021
LUXEMBOURG, June 29, 2021 – LMO, a company developing precision maneuvering technologies for in-space operations, with offices in Luxembourg and UK, secures funding from VIVES Inter-University Fund
Post date
15/06/2021
Mont-Saint-Guibert, June 15, 2021 – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs
Post date
31/03/2021
March 31, 2021 - Louvain-la-Neuve, Belgium: Tessares - a technology company specializing in Hybrid Access software - has just concluded a new round of funding to fast forward an innovative software
Post date
22/03/2021
LEUVEN, Belgium, March 22nd, 2021 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce
Post date
16/03/2021
Vaccines alone are not enough to fight Covid-19. Experts pinpointed during several occasions on the importance of having antibody-based treatments available in combination with vaccines.
This is
Post date
04/03/2021
Authorization to start clinical trial in the US granted for rare paediatric bone disease
Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a clinical stage company
Post date
27/01/2021
Belgium – 27th January 2021 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment
Post date
20/11/2020
New funding confirms Aphea.Bio’s frontrunner position in sustainable and innovative agriculture
GENT, NOVEMBER 20 - Aphea.Bio, a Belgium-based agtech startup, announced today that it secured a €14
Post date
24/11/2020
Tessares, a young company from Louvain-la-Neuve, has won an ultra-selective European subsidy of 1.2 million euros!
In Europe, more than 40% of homes in rural areas do not have a quality internet